ADVENT TECHNOLOGIES HOLDINGS (ADN) Stock Fundamental Analysis

NASDAQ:ADN • US00788A2042

0.9185 USD
-1.79 (-66.11%)
At close: Oct 29, 2025
0.88 USD
-0.04 (-4.19%)
After Hours: 10/29/2025, 8:12:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADN. ADN was compared to 91 industry peers in the Electrical Equipment industry. Both the profitability and financial health of ADN have multiple concerns. ADN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ADN has reported negative net income.
  • ADN had a negative operating cash flow in the past year.
  • ADN had negative earnings in each of the past 5 years.
  • In the past 5 years ADN always reported negative operating cash flow.
ADN Yearly Net Income VS EBIT VS OCF VS FCFADN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • ADN's Return On Assets of -612.77% is on the low side compared to the rest of the industry. ADN is outperformed by 95.65% of its industry peers.
Industry RankSector Rank
ROA -612.77%
ROE N/A
ROIC N/A
ROA(3y)-266.83%
ROA(5y)-195.57%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADN Yearly ROA, ROE, ROICADN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • With an excellent Gross Margin value of 54.58%, ADN belongs to the best of the industry, outperforming 97.83% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ADN has grown nicely.
  • ADN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.39%
GM growth 5Y8.72%
ADN Yearly Profit, Operating, Gross MarginsADN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • ADN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ADN has been increased compared to 1 year ago.
  • ADN has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ADN is higher compared to a year ago.
ADN Yearly Shares OutstandingADN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ADN Yearly Total Debt VS Total AssetsADN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -61.07, we must say that ADN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -61.07, ADN is doing worse than 93.48% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -61.07
ROIC/WACCN/A
WACC10.76%
ADN Yearly LT Debt VS Equity VS FCFADN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 0.05 indicates that ADN may have some problems paying its short term obligations.
  • ADN has a Current ratio of 0.05. This is amonst the worse of the industry: ADN underperforms 94.57% of its industry peers.
  • A Quick Ratio of 0.05 indicates that ADN may have some problems paying its short term obligations.
  • ADN has a Quick ratio of 0.05. This is amonst the worse of the industry: ADN underperforms 94.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
ADN Yearly Current Assets VS Current LiabilitesADN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 57.98% over the past year.
  • Looking at the last year, ADN shows a very strong growth in Revenue. The Revenue has grown by 113.28%.
  • ADN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.50% yearly.
EPS 1Y (TTM)57.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.71%
Revenue 1Y (TTM)113.28%
Revenue growth 3Y-22.61%
Revenue growth 5Y39.5%
Sales Q2Q%-87.7%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year91.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADN Yearly Revenue VS EstimatesADN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADN Yearly EPS VS EstimatesADN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ADN. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 9.09, the valuation of ADN can be described as reasonable.
  • ADN's Price/Forward Earnings ratio is rather cheap when compared to the industry. ADN is cheaper than 96.74% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.75. ADN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 9.09
ADN Price Earnings VS Forward Price EarningsADN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADN Per share dataADN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ADN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ADVENT TECHNOLOGIES HOLDINGS

NASDAQ:ADN (10/29/2025, 8:12:04 PM)

After market: 0.88 -0.04 (-4.19%)

0.9185

-1.79 (-66.11%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)10-20
Earnings (Next)12-26
Inst Owners8%
Inst Owner Change-81.11%
Ins Owners10.33%
Ins Owner Change0%
Market Cap3.02M
Revenue(TTM)3.28M
Net Income(TTM)-40.99M
Analysts45
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.09
P/S 0.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.65
EYN/A
EPS(NY)0.1
Fwd EY11%
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS1
BVpS-8.94
TBVpS-8.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -612.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.58%
FCFM N/A
ROA(3y)-266.83%
ROA(5y)-195.57%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.39%
GM growth 5Y8.72%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.55%
Cap/Sales 2.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -61.07
F-Score4
WACC10.76%
ROIC/WACCN/A
Cap/Depr(3y)123.72%
Cap/Depr(5y)228.29%
Cap/Sales(3y)123.53%
Cap/Sales(5y)88.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.71%
EPS Next Y600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)113.28%
Revenue growth 3Y-22.61%
Revenue growth 5Y39.5%
Sales Q2Q%-87.7%
Revenue Next Year91.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year760%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.33%
OCF growth 3YN/A
OCF growth 5YN/A

ADVENT TECHNOLOGIES HOLDINGS / ADN FAQ

What is the ChartMill fundamental rating of ADVENT TECHNOLOGIES HOLDINGS (ADN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ADN.


Can you provide the valuation status for ADVENT TECHNOLOGIES HOLDINGS?

ChartMill assigns a valuation rating of 3 / 10 to ADVENT TECHNOLOGIES HOLDINGS (ADN). This can be considered as Overvalued.


How profitable is ADVENT TECHNOLOGIES HOLDINGS (ADN) stock?

ADVENT TECHNOLOGIES HOLDINGS (ADN) has a profitability rating of 1 / 10.


What is the financial health of ADVENT TECHNOLOGIES HOLDINGS (ADN) stock?

The financial health rating of ADVENT TECHNOLOGIES HOLDINGS (ADN) is 0 / 10.